28 related articles for article (PubMed ID: 2867770)
1. Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
Karmi N; Sun S; Festen EAM; Vich Vila A; Gacesa R; Weersma RK
Gut; 2024 Apr; ():. PubMed ID: 38569847
[No Abstract] [Full Text] [Related]
2. Orthopraxy, not orthodoxy.
Emmanuel AV
Frontline Gastroenterol; 2018 Jan; 9(1):1. PubMed ID: 29484153
[No Abstract] [Full Text] [Related]
3. Risk and reward: rethinking the paradigm for adenoma surveillance.
Verma AM; Chilton AP
Frontline Gastroenterol; 2015 Apr; 6(2):75-76. PubMed ID: 28840906
[No Abstract] [Full Text] [Related]
4. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1-Effects on Solubility of Poorly Soluble Drugs.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Jun; 21(5):177. PubMed ID: 32592045
[TBL] [Abstract][Full Text] [Related]
5. Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.
Allgayer H; Rang S; Klotz U; Böhne P; Retey J; Kruis W; Gugler R
Dig Dis Sci; 1994 Jan; 39(1):145-51. PubMed ID: 8281849
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the degradation mechanism of 5-aminosalicylic acid in aqueous solution.
Palsmeier RK; Radzik DM; Lunte CE
Pharm Res; 1992 Jul; 9(7):933-8. PubMed ID: 1438009
[TBL] [Abstract][Full Text] [Related]
7. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
9. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.
Gu GZ; Xia HM; Pang ZQ; Liu ZY; Jiang XG; Chen J
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):449-56. PubMed ID: 21251889
[TBL] [Abstract][Full Text] [Related]
10. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography.
Brendel E; Meineke I; Witsch D; Zschunke M
J Chromatogr; 1987 Jan; 385():299-304. PubMed ID: 3558586
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
[TBL] [Abstract][Full Text] [Related]
13. Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites.
Allgayer H; Sonnenbichler J; Kruis W; Paumgartner G
Arzneimittelforschung; 1985; 35(9):1457-9. PubMed ID: 2867770
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
